论文部分内容阅读
许多临床观察和动物实验提示,肝性脑病和多种肝病时氨基酸代谢有明显改变,主要表现为血浆中芳香族氨基酸(Phe及Try,简称AAA)的浓度增高,支链氨基酸(Ile、Leu及Val,简称BCAA)的浓度减少,BCAA/AAA摩尔比值降低,这些血浆氨基酸的失衡与肝性脑病的发生、发展密切相关。因此可用BCAA(或以BCAA为主的混合氨基酸)注射液治疗肝性脑病及其它肝病患者,纠正血浆氨基酸的失调,取得一定的疗效。然而BCAA在体内的代谢和作用则是进一步认识其治疗作用,以便改进其组分及比例,提高疗效的基础。
Many clinical observations and animal experiments suggest that amino acid metabolism in hepatic encephalopathy and various liver diseases is significantly altered. The main manifestations are the increased concentration of aromatic amino acids (Phe and Try, AAA for short), branched chain amino acids (Ile, Leu, Val, referred to as BCAA) decreased, BCAA / AAA molar ratio decreased, the imbalance of these plasma amino acids and hepatic encephalopathy is closely related to the development. Therefore, BCAA (or BCAA-based mixed amino acids) injection can be used to treat patients with hepatic encephalopathy and other liver diseases to correct the imbalance of plasma amino acids and achieve a certain effect. However, BCAA metabolism and role in the body is to further understand its therapeutic effect, in order to improve its composition and proportion, to improve the basis of the effect.